-
公开(公告)号：US20120258442A1
公开(公告)日：2012-10-11
申请号：US13083552
申请日：2011-04-09
Applicant: Mark Erlander , Xiao-Jun Ma
Inventor： Mark Erlander , Xiao-Jun Ma
CPC classification number: C12Q1/6888 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/16
Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
Abstract translation: 本公开提供了使用基因表达测量法在例如在福尔马林固定，石蜡包埋（FFPE）样品的情况下从临床环境中从受试者获得的样品中的54种癌症类型中进行分类或鉴定的方法。
-
公开(公告)号：US20120196761A1
公开(公告)日：2012-08-02
申请号：US13196818
申请日：2011-08-02
Applicant: XIAO-JUN MA , Mark Erlander , Sgroi Dennis
Inventor： XIAO-JUN MA , Mark Erlander , Sgroi Dennis
CPC classification number: C07K14/4748 , C07K14/47 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N33/57415 , G01N2333/96494 , G01N2800/52 , G01N2800/54
Abstract: The disclosure includes the use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the disclosure provides the identities of genes that are expressed in correlation with the presence of breast cancer, the grade of breast cancer, and the type of breast cancer. The disclosed methods assist in the detection and identification of breast cancer in a patient and so helps determine treatment and clinical outcome, and so prognosis, for the patient. The gene expression levels, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used detect the presence of in situ or invasive breast cancer.
Abstract translation: 本公开包括使用与乳腺癌临床相关的基因表达谱或模式。 特别地，本公开提供了与乳腺癌的存在，乳腺癌的级别和乳腺癌的类型相关表达的基因的身份。 所公开的方法有助于检测和鉴定患者中的乳腺癌，因此有助于确定患者的治疗和临床结果以及预后。 可以使用基因表达水平，无论是体现在核酸表达，蛋白质表达或其他表达形式中，都可以检测原位或浸润性乳腺癌的存在。
-
公开(公告)号：US20060234287A1
公开(公告)日：2006-10-19
申请号：US11426572
申请日：2006-06-26
Applicant: Mark Erlander , Xia-Jun Ma , Dennis Sgroi
Inventor： Mark Erlander , Xia-Jun Ma , Dennis Sgroi
IPC: C12Q1/68
CPC classification number: G01N33/57415 , C12Q1/6886 , C12Q2600/158 , G01N33/57496 , Y02A90/22
Abstract: Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.
Abstract translation: 提供了用于鉴定乳腺癌进展特征的方法和组合物。 基于来自独立乳腺癌病例的参考乳腺组织样本的多次取样来识别签名谱，并且提供用于鉴定细胞在乳腺癌的一个或多个特定阶段中的可靠的一组分子标准。
-
公开(公告)号：US20050100933A1
公开(公告)日：2005-05-12
申请号：US10871869
申请日：2004-06-18
Applicant: Mark Erlander , Xiao-Jun Ma , Wei Wang , James Wittliff
Inventor： Mark Erlander , Xiao-Jun Ma , Wei Wang , James Wittliff
IPC: C12P19/34 , C12Q1/68 , G01N33/574
CPC classification number: G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
Abstract: The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.
Abstract translation: 本发明提供了与乳腺癌临床相关的基因表达谱或模式的鉴定和使用。 特别地，本发明提供了与患者存活和乳腺癌复发相关的基因的身份。 基因表达谱可以体现在核酸表达，蛋白质表达或其他表达形式中，并用于预测患有乳腺癌的受试者的存活并预测乳腺癌复发。 轮廓也可以用于乳腺癌细胞和组织的研究和/或诊断，包括浸润性乳腺癌的分级，以及用于研究和/或确定患者的预后。 当用于诊断或预后时，可根据预期寿命和复发的可能性来确定乳腺癌的治疗方法。
-
公开(公告)号：US06413743B1
公开(公告)日：2002-07-02
申请号：US09642855
申请日：2000-08-21
Applicant: Timothy W. Lovenberg , Mark Erlander , Arne Huvar , Jayashree Pyati
Inventor： Timothy W. Lovenberg , Mark Erlander , Arne Huvar , Jayashree Pyati
IPC: C12N510
CPC classification number: C07K14/723 , C12N2799/026
Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
-
Patent Agency Ranking
公开(公告)号：US20050255481A1
公开(公告)日：2005-11-17
申请号：US10843717
申请日：2004-05-11
Applicant: Xiao-Jun Ma , Edward Enright , Mark Erlander
Inventor： Xiao-Jun Ma , Edward Enright , Mark Erlander
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
Abstract: The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.
Abstract translation: 本发明涉及鉴定和使用与乳腺癌相关的来自表达的孕酮受体转录物的序列。 特别地，本发明提供可用于鉴定对雌激素受体表达呈阳性的群体的多核苷酸序列的身份。 表达的多核苷酸序列可用于研究和/或诊断乳腺癌中的细胞和组织，以及用于研究和/或确定患者的预后。
-
公开(公告)号：US20050130194A1
公开(公告)日：2005-06-16
申请号：US10942252
申请日：2004-09-15
Applicant: Mark Erlander , Ranelle Salunga
Inventor： Mark Erlander , Ranelle Salunga
CPC classification number: C12Q1/686 , C12N15/1096 , C12Q1/6865 , C12Q2525/173 , C12Q2525/143
Abstract: The present invention provides methods for the amplification of nucleic acid molecules. Methods for amplifying target polynucleotides, including mRNA, using oligonucleotides, DNA and RNA polymerases are provided. The invention further provides compositions and kits for practicing the methods, as well as methods which use the amplification products.
Abstract translation: 本发明提供了扩增核酸分子的方法。 提供了使用寡核苷酸，DNA和RNA聚合酶扩增靶多核苷酸（包括mRNA）的方法。 本发明还提供了用于实施该方法的组合物和试剂盒，以及使用扩增产物的方法。
-
公开(公告)号：US20060246434A1
公开(公告)日：2006-11-02
申请号：US10507932
申请日：2003-03-14
Applicant: Mark Erlander , Ranelle Salunga , Theresa Taylor , Liang You , Steven Kunitake
Inventor： Mark Erlander , Ranelle Salunga , Theresa Taylor , Liang You , Steven Kunitake
CPC classification number: C12P19/34 , C12N15/1096 , C12Q1/6846 , C12Q2525/179 , C12Q2525/143 , C12Q2521/107
Abstract: A method of processing images includes the steps of retrieving a source image file including pixel date, creating a destination image file buffer, mapping the pixel data from the source image file to the destination image file buffer, and outputting pixel, data from the destination image file buffer as a destination image file. The step of mapping pixel data from the source image file to the destination image file buffer can include the step of interpolating the source image pixel data to produce pixel date for the destination image file buffer. Border pixel data can be added to the source image file to improve the efficiency interpolation step. The source image file can be a panoramic projection image file, and can include pixel data from a plurality of images. An apparatus for processing images in accordance with the method is also provided.
Abstract translation: 处理图像的方法包括以下步骤：检索包括像素日期的源图像文件，创建目的地图像文件缓冲器，将源图像文件的像素数据映射到目的地图像文件缓冲器，以及从目的地图像输出像素数据 文件缓冲区作为目标映像文件。 将像素数据从源图像文件映射到目的地图像文件缓冲器的步骤可以包括内插源图像像素数据以产生目标图像文件缓冲器的像素日期的步骤。 可以将边缘像素数据添加到源图像文件中，以提高效率插值步骤。 源图像文件可以是全景投影图像文件，并且可以包括来自多个图像的像素数据。 还提供了一种根据该方法处理图像的装置。
-
公开(公告)号：US20060154267A1
公开(公告)日：2006-07-13
申请号：US11089097
申请日：2005-03-24
Applicant: Xiao-Jun Ma , Mark Erlander , Dennis Sgroi , Edward Enright
Inventor： Xiao-Jun Ma , Mark Erlander , Dennis Sgroi , Edward Enright
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158 , G06Q50/22
Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.
Abstract translation: 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与反应性或缺乏相关，与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本，并提供可靠的一组分子标准，用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物，用于通过使用多种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种抗雌激素剂对乳腺癌的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而另外两种生物标志物显示与他莫昔芬反应相关的降低的表达。
-
公开(公告)号：US20050239083A1
公开(公告)日：2005-10-27
申请号：US10773761
申请日：2004-02-06
Applicant: Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
Inventor： Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158
Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
Abstract translation: 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与反应性或缺乏相关，与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本，并提供可靠的一组分子标准，用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物，用于通过使用三种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种针对乳腺癌的抗雌激素剂的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.025 seconds)
